Pau Marc Muñoz Torres, N/A

Vall d'Hebron Institute of Oncology (VHIO), Spain

N/A

Poster(s):

• 1111 - Immune-profiling of ibrutinib-treated CLL patients revealed TMBIM6 as a potential target for CLL and its high expression as an independent variable associated with poor prognosis